Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Conditions
Interventions
Zanzalintinib
Everolimus
Locations
80
United States
Exelixis Clinical Site #43
Birmingham, Alabama, United States
Exelixis Clinical Site #36
Phoenix, Arizona, United States
Exelixis Clinical Site #42
Tucson, Arizona, United States
Exelixis Clinical Site #18
Beverly Hills, California, United States
Exelixis Clinical Site #16
Los Angeles, California, United States
Exelixis Clinical Site #54
Palo Alto, California, United States
Start Date
July 21, 2025
Primary Completion Date
June 1, 2029
Completion Date
June 1, 2029
Last Updated
April 17, 2026
Lead Sponsor
Exelixis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions